Incb28060

Col1a2-creER^T2 mice and Rosa26R-tdTomato reporter mice were purchased form The Jackson Laboratory. Ikkβ^F/F have been described previously (Greten et al., 2004 (link)). All mice including cre-negative littermate controls were crossed on a FVB background for at least four generations and in all experiments littermate controls were used. To ensure sustained recombination mice were kept on a diet containing tamoxifen (400 mg/kg; LASvendi) throughout the duration of the CAC model. AOM/DSS-induced tumorigenesis was performed essentially as previously described (Bollrath et al., 2009 (link)). 10 mg/kg AOM (Sigma-Aldrich) was injected i.p. at day 0, 5 d before mice received 2% DSS (MP Biosystems) in the drinking water for 5 d, followed by 16 d of regular water, which was repeated twice. Severity of colitis was assessed histologically as described before (Eckmann et al., 2008 (link)). The c-Met inhibitor INCB28060 (capmatinib) was purchased from Selleckchem and incorporated (18 mg/kg) along with tamoxifen (400 mg/kg) into rodent diet AIN-76A (Research Diets, Inc.). Control groups received tamoxifen containing AIN-76A diet only. All experiments were approved by the Regierungspräsidium Darmstadt.

Antibodies, RNAi oligomers, and phosphopeptides used are listed in the Supplemental Experimental Procedures. HGF, NGF, and cycloheximide were purchased from Sigma. PHA665752, SU1174, and bovine plasma fibronectin were purchased from Calbiochem, and INCB28060 was purchased from Selleckchem.